Table 2. Clinical factors related to TEG-MAADP measured after 5-day ticagrelor maintenance treatment in ticagrelor treated ACS patients (n = 176).
| Variables | β coefficient | 95% CI | *Adjusted P value |
| Age (in decades) | 1.13 | 0.99 to 3.26 | 0.29 |
| Female gender | 2.64 | –2.79 to 8.07 | 0.34 |
| BMI (per 5 kg/m2) | 1.11 | –3.81 to 15.90 | 0.65 |
| Current smoking status | –1.72 | –5.87 to 2.43 | 0.41 |
| Diabetes mellitus | –1.52 | –5.37 to 2.32 | 0.46 |
| Renal dysfunction | 9.75 | –14.37 to 33.87 | 0.43 |
| PPI | 3.80 | –1.85 to 9.45 | 0.19 |
| Statins | –3.19 | –14.04 to 7.66 | 0.56 |
| CCB | –4.08 | –7.96 to –0.20 | 0.04 |
| LVEF | –0.31 | –0.57 to –0.05 | 0.02 |
| Platelet count | 0.02 | –0.01 to 0.05 | 0.29 |
| eGFR (per 30 mL/min per 1.73 m2) | 0.05 | –0.06 to 0.15 | 0.38 |
*Adjusted by the baseline demographic [gender, age (in decades), BMI (per 5 kg/m2), smoking status and comorbidities (diabetes mellitus, renal dysfunction), co-medications (PPI, statins, CCB), laboratory examination [LVEF, platelet count and creatinine-based eGFR (per 30 mL/min per 1.73 m2)]. ACS: acute coronary syndrome; BMI: body mass index; CCB: calcium channel blockers; eGFR: estimates of the glomerular filtrationrate; LVEF: left ventricular ejection; MAADP: ADP-induced platelet-fibrin clot strength; PPI: proton pump inhibitor; TEG: thrombelastography.